References
de Buy M, Wenniger L, Terpstra V, Beuers U (2010) Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology. Dig Surg 27(1):24–31
Rooks JB, Ory HW, Ishak KG et al (1979) Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 242(7):644–648
Socas L, Zumbado M, Pérez-Luzardo O et al (2005) Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med 39(5):27
Oshita A, Itamoto T, Amano H et al (2008) Perioperative management of benign hepatic tumors in patients with glycogen storage disease type Ia. J Hepatobiliary Pancreat Surg 15(2):200–203
Resnick MB, Kozakewich HP, Perez-Atayde AR (1995) Hepatic adenoma in the pediatric age group. Clinicopathological observations and assessment of cell proliferative activity. Am J Surg Pathol 19(10):1181–1190
Levy RH, Mattson RH, Meldrum BS et al (2002) Antiepileptic drugs, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 528–540
Clemmesen J, Hjalgrim-Jensen S (1978) Is phenobarbital carcinogenic? A follow-up of 8078 epileptics. Ecotoxicol Environ Saf 1(4):457–470
Clemmesen J, Hjalgrim-Jensen S (1981) Does phenobarbital cause intracranial tumors? A follow-up through 35 years. Ecotoxicol Environ Saf 5(2):255–260
White SJ, McLean AE, Howland C (1979) Anticonvulsant drugs and cancer. A cohort study in patients with severe epilepsy. Lancet 2(8140):458–461
Olsen JH, Boice JD Jr, Jensen JP, Fraumeni JF Jr (1989) Cancer among epileptic patients exposed to anticonvulsant drugs. J Natl Cancer Inst 81(10):803–808
Olsen J, Wallin H, Boice JD Jr et al (1993) Phenobarbital, drug metabolism, and human cancer. Cancer Epidemiol Biomarkers Prev 2(5):449–452
Lamminpää A, Pukkala E, Teppo L, Neuvonen PJ (2002) Cancer incidence among patients using antiepileptic drugs: a long-term follow-up of 28,000 patients. Eur J Clin Pharmacol 58(2):137–141
Peraino C, Fry RJ, Staffeldt E (1971) Reduction and enhancement by phenobarbital of hepatocarcinogenesis induced in the rat by 2-acetylaminofluorene. Cancer Res 31(10):1506–1512
Driver HE, McLean AE (1986) Dose–response relationships for initiation of rat liver tumours by diethylnitrosamine and promotion by phenobarbitone or alcohol. Food Chem Toxicol 24(3):241–245
Diwan BA, Rice JM, Nims RW et al (1988) P-450 enzyme induction by 5-ethyl-5-phenylhydantoin and 5,5-diethylhydantoin, analogues of barbiturate tumor promoters phenobarbital and barbital, and promotion of liver and thyroid carcinogenesis initiated by N-nitrosodiethylamine in rats. Cancer Res 48(9):2492–2497
Singh G, Driever PH, Sander JW (2005) Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 128(Pt 1):7–17
Lautz TB, Finegold MJ, Chin AC, Superina RA (2008) Giant hepatic adenoma with atypical features in a patient on oxcarbazepine therapy. J Pediatr Surg 43(4):751–754
Seki A, Inoue T, Maegaki Y et al (2006) Polycystic ovary syndrome and hepatocellular adenoma related to long-term use of sodium valproate in a young woman. No To Hattatsu 38(3):205–208
Tazawa K, Yasuda M, Ohtani Y et al (1999) Multiple hepatocellular adenomas associated with long-term carbamazepine. Histopathology 35(1):92–94
Rignall B, Braeuning A, Buchmann A, Schwarz M (2011) Tumor formation in liver of conditional β-catenin-deficient mice exposed to a diethylnitrosamine/phenobarbital tumor promotion regimen. Carcinogenesis 32(1):52–57
Phillips JM, Goodman JI (2009) Multiple genes exhibit phenobarbital-induced constitutive active/androstane receptor-mediated DNA methylation changes during liver tumorigenesis and in liver tumors. Toxicol Sci 108(2):273–289
Phillips JM, Burgoon LD, Goodman JI (2009) Phenobarbital elicits unique, early changes in the expression of hepatic genes that affect critical pathways in tumor-prone B6C3F1 mice. Toxicol Sci 109(2):193–205
Klaunig JE (1993) Selective induction of DNA synthesis in mouse preneoplastic and neoplastic hepatic lesions after exposure to phenobarbital. Environ Health Perspect 101(Suppl 5):235–239
Hyman GA, Sommers SC (1966) The development of Hodgkin's disease and lymphoma during anticonvulsant therapy. Blood 28(3):416–427
Kruger GR, Harris D (1972) Is phenytoin carcinogenic? Lancet 1(7745):323
Vázquez JJ, Marigil MA (1989) Liver-cell adenoma in an epileptic man on barbiturates. Histol Histopathol 4(3):301–303
Ferko A, Bedrna J, Nozicka J (2003) Pigmented hepatocellular adenoma of the liver caused by long-term use of phenobarbital. Rozhl Chir 82(4):192–195
Warner KA, Fernstrom MJ, Ruch RJ (2003) Inhibition of mouse hepatocyte gap junctional intercellular communication by phenobarbital correlates with strain-specific hepatocarcinogenesis. Toxicol Sci 71(2):190–197
Michelucci R (2006) Optimizing therapy of seizures in neurosurgery. Neurology 67(12 Suppl 4):S14–S18
Author contributions
The authors of this case report actively participated in patient care and post-discharge follow-up.
Declaration of conflicting interests
The authors declared no potential conflicts of interest with respect to the authorship and/or publication of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cerminara, C., Bagnolo, V., De Leonardis, F. et al. Hepatocellular adenoma associated with long-term exposure to phenobarbital: a paediatric case report. Childs Nerv Syst 28, 939–941 (2012). https://doi.org/10.1007/s00381-011-1636-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00381-011-1636-1